BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Company Sees Opportunity For A Similar Ramp-Up For The Cardiovascular Drug
Executive Summary
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.
You may also be interested in...
Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
Third Rock Thinks Its Model Reassures Investors In Difficult Times
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.